A new population-based study found that HbA1c screening in adults aged 40-70 years reduced the time to diabetes diagnosis by a median of 2.2 years when compared with routine clinical care.
Undiagnosed diabetes can be detected by screening programs much earlier than symptomatic or incidental diagnosis. But the improvement in time to diagnosis achieved by screening programs compared with routine clinical care is uncertain. Hence researchers conducted a study to estimate the reduction in time to diabetes diagnosis achieved by HbA1c-based screening in middle-aged adults.
Using the UK Biobank population-based study, participants aged 40-70 years were taken into the study by measuring the HbA1c at enrolment. Primary and secondary healthcare data were linked and those with a pre-existing diabetes diagnosis were identified. Among the remaining participants without a diabetes diagnosis, an elevated enrolment HbA1c level was used (≥48 mmol/mol [≥6.5%]) to identify those with undiagnosed diabetes. Kaplan-Meier analysis was used to assess the time between enrolment HbA1c measurement and subsequent clinical diabetes diagnosis up to 10 years, and Cox regression was used to identify clinical factors associated with a delayed diabetes diagnosis.
Results:
- In total, 1.0% of participants without a diabetes diagnosis had undiagnosed diabetes based on calibrated HbA1c levels at UK Biobank enrolment, with a median HbA1c level of 51.3 mmol/mol (IQR 49.1-57.2) (6.8% [6.6-7.4]).
- These participants represented an additional 13.0% of diabetes cases in the study population relative to the 13,077 participants with a diabetes diagnosis.
- The median time to clinical diagnosis for those with undiagnosed diabetes was 2.2 years, with a median HbA1c at a clinical diagnosis of 58.2 mmol/mol (IQR 51.0-80.0) (7.5% [6.8-9.5]).
- Female participants with lower HbA1c and BMI measurements at enrolment experienced the longest delay to clinical diagnosis.
When compared to standard clinical care, this is the first population-based study on adults between the ages of 40 and 70 that demonstrated HbA1c screening can speed up the diagnosis of diabetes by a median of 2.2 years. The findings support the use of HbA1c screening to cut down on the amount of time people live with diabetes without being diagnosed.
Further reading: Young KG, McGovern AP, Barroso I, et al. The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis [published online ahead of print, 2022 Nov 22]. Diabetologia. 2022;10.1007/s00125-022-05824-0. doi:10.1007/s00125-022-05824-0
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.